Cargando…
Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
Autores principales: | Concordet, D., Gandia, P., Montastruc, J. L., Bousquet-Mélou, A., Lees, P., Ferran, A. A., Toutain, P. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007435/ https://www.ncbi.nlm.nih.gov/pubmed/31802401 http://dx.doi.org/10.1007/s40262-019-00848-z |
Ejemplares similares
-
Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
por: Concordet, Didier, et al.
Publicado: (2019) -
Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?
por: Concordet, Didier, et al.
Publicado: (2019) -
Authors’ Reply to Nicolas: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019) -
Authors’ Reply to Coste et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019) -
Authors’ Reply to Lechat et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019)